




## Revista Brasileira de Hematologia e Hemoterapia Brazilian Journal of Hematology and Hemotherapy

www.rbhh.org



### Scientific comment

## Comment on “Outcomes of autologous transplantation for multiple myeloma according to different induction regimens”<sup>☆</sup>

Javier de la Rubia<sup>a,b,\*</sup>

<sup>a</sup> University Hospital La Fe, Valencia, Spain

<sup>b</sup> Universidad Católica de Valencia “San Vicente Mártir”, Valencia, Spain

Treatment of multiple myeloma (MM) has changed significantly in the past decade as a result of better understanding of disease biology, more effective treatments, and improved supportive care. Autologous stem cell transplantation (ASCT) is an effective treatment for myeloma and remains a critical component for its management. The goal of initial therapy remains the same, rapid disease control, and the introduction of new drugs such as thalidomide, bortezomib, and lenalidomide has enabled us to achieve this goal; combinations of these drugs have also led to unprecedented depth of response. On the other hand, the availability of these new drugs has given way to numerous double, triple, and quadruple combinations; nevertheless there is a striking paucity of randomized data to enable physicians to choose the best treatment for initial therapy. Moreover, most available randomized trials are comparisons of newer treatments against older alkylator- or anthracycline-based treatments. Thus, in the absence of randomized studies comparing different induction regimens, it is difficult to recommend one induction treatment over another.

Thalidomide is active in MM and produces little hematologic toxicity, indicating that it may be preferred for use as induction therapy. Several studies evaluating thalidomide, as a component of induction therapy, have shown that it improves response rates<sup>1-8</sup> and progression-free survival (PFS)<sup>2,3,5,6,9</sup> and provides similar<sup>5,6,9</sup> or improved overall survival (OS)

rates versus non-thalidomide containing treatment.<sup>3</sup> The demonstrated efficacy, lack of myelosuppression, and overall tolerability of thalidomide provide a strong reason for its incorporation in standard induction treatment in patients with newly diagnosed MM who may be eligible for ASCT. In the last issue of the *Revista Brasileira de Hematologia e Hemoterapia*, the article of Crusoe et al. show the results of a retrospective study comparing pre-transplant induction therapy with conventional chemotherapy (VAD) versus thalidomide and dexamethasone (TD) or TD plus cyclophosphamide (CTD) in 152 patients with newly diagnosed MM undergoing front-line ASCT (Table 1).<sup>10</sup> Although no differences in OS or PFS were found between the three groups, the rate of very good partial response or better response, both before and after ASCT, was higher with treatments that included thalidomide. The retrospective design of the study, the fact that only patients with at least partial response were included, and the small number of patients in each group can help explain the absence of significant differences in the follow-up. However, in the context of emerging data from ongoing trials using bortezomib and lenalidomide combinations, the improvement obtained with CTD may just not be the best that can be obtained with current therapy. Large, randomized trials are currently under way to address this and other clinically relevant questions in myeloma therapy today. Despite these limitations, until additional randomized data is available, the choice for initial

<sup>☆</sup>See paper by Crusoe EQ et al, on Rev Bras Hematol Hemoter. 2014;36(1):19-24.

\*Corresponding author at: Hematology Service, University Hospital La Fe, Bulevar Sur, s/n, 46026, Valencia, Spain.

E-mail address: delarubia\_jav.@gva.es (J. Rubia).

**Table 1 - Results of different induction treatments for newly diagnosed multiple myeloma patients eligible for transplantation.**

Regimen	Overall response rate (%)	Very good partial response or greater (%)	Complete response (%)
TD +/- Alkylating	60-70	30-40	5
TD + Bortezomib	80-90	50-60	30
Lenalidomide and dexamethasone	80-90	40-50	15
Lenalidomide + bortezomib + others	100	60	30-40

TD: thalidomide and dexamethasone.

therapy is often driven by opinion and, more importantly, by local social or economic boundaries, circumstances that have been clearly pointed out by the authors of this paper.

In summary, the results of this study clearly confirm the superiority of thalidomide-based treatments versus conventional chemotherapy for the frontline treatment of MM patients, and strongly support the use of thalidomide as part of the induction regimen in MM patients eligible for ASCT.

### Conflicts of interest

The author declares no conflicts of interest.

### REFERENCES

- Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. *J Clin Oncol.* 2006;24(3):431-6.
- Rajkumar SV, Rosiñol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. *J Clin Oncol.* 2008;26(13):2171-7.
- Zervas K, Mihou D, Katodritou E, Pouli A, Mitsouli CH, Anagnostopoulos A, et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. *Ann Oncol.* 2007;18(8):1369-75.
- Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. *Haematologica.* 2008;93(1):124-7.
- Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. *Blood.* 2010;115(6):1113-20.
- Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. *N Engl J Med.* 2006;354(10):1021-30.
- Macro M, Divine M, Uzunhan Y, Jaccard A, Bouscary D, Leblond V, et al. Dexamethasone+thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial. *Blood.* 2006;108:Abstract 57.
- Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, et al. National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. *Haematologica* 2012;97(3):442-450.
- Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, et al. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. *Am J Hematol.* 2007;82(12):1071-5.
- Crusoe EQ, Higashi F, Padilha MP, Miranda EC, Quero AA, Almeida MS, et al. Outcomes of autologous transplantation for multiple myeloma according to different induction regimens. *Rev Bras Hematol Hemoter.* 2014;36(1):19-24.